Omeros (NASDAQ:OMER) Trading Up 5.3% – Here’s What Happened

Omeros Co. (NASDAQ:OMER) shares shot up 5.3% during trading on Monday . The company traded as high as $8.86 and last traded at $8.82. 288,671 shares traded hands during trading, a decline of 52% from the average session volume of 598,501 shares. The stock had previously closed at $8.37.

Wall Street Analyst Weigh In

A number of brokerages have commented on OMER. RODMAN&RENSHAW upgraded shares of Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price objective on shares of Omeros in a report on Thursday, January 16th. StockNews.com raised shares of Omeros from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Rodman & Renshaw began coverage on shares of Omeros in a report on Thursday, November 14th. They set a “buy” rating and a $9.00 price objective for the company. Finally, Needham & Company LLC reissued a “hold” rating on shares of Omeros in a report on Friday, January 17th. Three investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Stock Up 5.4 %

The firm has a market cap of $511.29 million, a price-to-earnings ratio of -3.81 and a beta of 2.01. The business’s fifty day moving average is $9.72 and its two-hundred day moving average is $6.21.

Institutional Trading of Omeros

A number of institutional investors have recently bought and sold shares of OMER. Wellington Management Group LLP acquired a new stake in Omeros during the 3rd quarter worth $305,000. Barclays PLC boosted its position in shares of Omeros by 121.3% during the third quarter. Barclays PLC now owns 94,640 shares of the biopharmaceutical company’s stock worth $376,000 after purchasing an additional 51,873 shares in the last quarter. Stordahl Capital Management Inc. bought a new position in shares of Omeros during the fourth quarter worth $395,000. AQR Capital Management LLC bought a new position in shares of Omeros during the second quarter worth $105,000. Finally, SG Americas Securities LLC bought a new position in shares of Omeros during the third quarter worth $80,000. Institutional investors and hedge funds own 48.79% of the company’s stock.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.